PetMed Express Faces Financial Reporting Issues

TL;DR

PetMed Express might have messed up its old financials, need to check.

AI Summary

PetMed Express, Inc. filed an 8-K on October 7, 2025, reporting material impairments and a non-reliance on previously issued financial statements. The filing indicates potential issues with past financial reporting, requiring further investigation and restatement. The company is based in Delray Beach, Florida.

Why It Matters

This filing suggests that PetMed Express's past financial statements may be unreliable, potentially impacting investor confidence and requiring significant accounting adjustments.

Risk Assessment

Risk Level: high — The company is disclaiming reliance on previously issued financial statements, indicating a significant accounting or reporting issue.

Key Players & Entities

• PETMED EXPRESS INC (company) — Registrant
• October 1, 2025 (date) — Earliest event reported
• October 7, 2025 (date) — Filing date
• Delray Beach, Florida (location) — Principal executive offices
• 420 South Congress Avenue (address) — Principal executive offices

FAQ

Key Financial Figures

• $1.2 million — Company's management, concluded that a $1.2 million non-cash impairment of the Company's PC
• $6,969,000 — ve decreased net sales by approximately $6,969,000 and correspondingly decreased cost of s
• $9,010,000 — ve decreased net sales by approximately $9,010,000 and correspondingly decreased cost of s
• $50 — ints; (ii) a fiscal fourth quarter 2025 $50 coupon promotion to customers and wheth
• $133,189 — esult, the Company erroneously recorded $133,189 in revenue associated with the December
• $1,101,151 — cember 31, 2024 of fiscal year 2025 and $1,101,151 in revenue associated with the March Ac
• $100 m — n a minimum purchase requirement, but a $100 minimum was later added after management
• $0 — ount (sale amount less coupon value) of $0. Prior to the investigation, management
• $2,451 — for the quarter ending March 31, 2025, $2,451 in expenses for the 74 orders with no n
• $711,897 — (vi) In April 2025, the Company accrued $711,897 for cooperative marketing funds for the
• $287,000 — sets and increased marketing expense by $287,000 for the quarter ended March 31, 2025. T

Filing Documents

• pets-20251001.htm (8-K) — 51KB
• 0001040130-25-000064.txt ( ) — 212KB
• pets-20251001.xsd (EX-101.SCH) — 2KB
• pets-20251001_def.xml (EX-101.DEF) — 16KB
• pets-20251001_lab.xml (EX-101.LAB) — 27KB
• pets-20251001_pre.xml (EX-101.PRE) — 16KB
• pets-20251001_htm.xml (XML) — 4KB

06. Material Impairments

Item 2.06. Material Impairments. On October 1, 2025, the Audit Committee of the Board of Directors (the "Audit Committee") of PetMed Express, Inc. (the "Company"), upon the recommendation of the Company's management, concluded that a $1.2 million non-cash impairment of the Company's PCRX trade name is required to be recorded in the quarter ended March 31, 2025. The Company acquired certain intangible assets, including the PCRX trade name, in its April 2023 acquisition of the issued and outstanding equity interests of PetCareRx. The acquired PCRX trade name, an indefinite-lived intangible asset, is not being amortized and is subject to a review for impairment on an annual basis, or more frequently if circumstances indicate an impairment may have occurred. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company determines the fair value of the PCRX trade name using the relief from royalty method, which assumes that trade names have value to the extent their owner is relieved from paying royalties for the benefits received. The relief from royalty method involves the application of estimated royalty rates to projected revenue streams, which are discounted to present value to estimate the cost savings associated with ownership of the asset. Following the Company's annual impairment testing in fiscal year 2025 and its ongoing review of such matters in connection with the expected filing of its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, while there was no single determinative event or factor, the reduction in actual and forecasted revenues related to the PCRX trade name led the Audit Committee to conclude that it was more likely than not that the fair value of the trade name was less than its book value. As result, the Audit Committee concluded there was a $1.2 million impairment of the Company's PCRX trade name. The Company does n

02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. (a) On October 1, 2025, the Company's Audit Committee, in consultation with management and RSM US LLP, the Company's independent registered public accounting firm ("RSM"), concluded that the financial statements for the years ended March 31, 2024 and 2023, as included in the Annual Report on Form 10-K for the year ended March 31, 2024 (the "2024 Annual Report"), along with the unaudited condensed consolidated financial statements in the Quarterly Reports on Form 10-Q for the quarterly periods within those years (the "Historical Quarterly Reports"), and the unaudited condensed consolidated financial statements in the Quarterly Reports for the quarters ended June 30, 2024 ("Q1 2025 Quarterly Report"), September 30, 2024 ("Q2 2025 Quarterly Report"), and December 31, 2024 ("Q3 2025 Quarterly Report") (collectively referred to as the "Reports" and the financial statements included therein as the "Affected Financials"), should no longer be relied upon, as a result of the income statement classification errors described below. These financial statements will be restated in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025. In addition, as a result of the foregoing determination, related press releases, shareholder communications, investor presentations and other communications describing relevant portions of the Affected Financials should no longer be relied upon. The Company expects that this restatement will be isolated to classification errors in the statement of operations included in the Affected Financials and will not impact any other financial statements in the Affected Financials, including the consolidated balance sheet, statement of changes in shareholders' equity, and statement of cash flows. The Company does not expect that this restatement of the Affected Financials, which is described in more detail b

01. Other Information

Item 8.01. Other Information. Update on Completion of Audit Committee Investigation and Status of 10-K Filing On October 7, 2025, the Company publicly reported the conclusion of the previously disclosed investigation by the Company's Audit Committee. As previously reported, the Company was unable to file, within the prescribed time period, its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, following the commencement of an investigation by the Audit Committee that was originally disclosed in the Company's Current Report on Form 8-K filed on July 1, 2025. The Audit Committee, assisted by outside legal counsel, Foley & Lardner LLP, and forensic accountants, BDO USA, P.C., conducted during June through August 2025 an investigation into allegations raised by two separate reports submitted anonymously through the Company's third-party-administered whistleblower hotline on April 15 and 16, 2025 regarding (i) the timing of revenue recognition with respect to certain AutoShip orders in the fiscal fourth quarter of 2025, some of which resulted in customer complaints; (ii) a fiscal fourth quarter 2025 $50 coupon promotion to customers and whether it was motivated to any extent by its potential impact on Company KPIs regarding new customers; and (iii) the Company's culture and control environment. The investigation's scope also ultimately included additional matters identified during the course of the investigation. The Audit Committee's primary investigative findings in the investigation included the following: (i) The Company accelerated shipment of products to AutoShip customers from the fourth quarter of fiscal year 2025 (i.e., the quarter ending March 31, 2025) to the third quarter of fiscal year 2025 (i.e., the quarter ending December 31, 2024) (the "December Accelerated Shipments") and again from the first quarter of fiscal year 2026 (i.e., the 3 quarter ending June 30, 2025) to the fourth quarter of fiscal year 2025 (i.e., the quarter end

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 7, 2025 PETMED EXPRESS, INC. By: /s/ Robert Lawsky Name: Robert Lawsky Title: General Counsel 6

View Full Filing

View this 8-K filing on SEC EDGAR